Mounjaro tirzepatide workers compensation claims: a practical guide for claims managers

Workers Compensation

Mounjaro tirzepatide workers compensation claims are appearing more often. The drug is TGA-approved for obesity but not PBS-listed, so claims managers need clear criteria to assess causation, cost, and clinical necessity.

What is Mounjaro tirzepatide?

Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly. Tirzepatide is a dual agonist of two incretin hormone receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The dual mechanism distinguishes it from older GLP-1 only agents such as semaglutide.

By mimicking both GLP-1 and GIP, tirzepatide reduces appetite by acting on the brain's satiety centres, slows gastric emptying so the stomach empties food more gradually, and improves blood sugar regulation by stimulating insulin release when glucose levels are elevated. In the SURMOUNT-1 clinical trial involving adults with obesity but without diabetes, participants on the highest tirzepatide dose achieved an average weight loss of approximately 21 percent of their body weight over 72 weeks.

It is administered by subcutaneous injection once weekly, with doses titrated upward from 2.5 mg to a maximum of 15 mg depending on tolerability and clinical response.

TGA-approved indications and PBS status in Australia

Tirzepatide has received TGA approval in three steps. First, for type 2 diabetes management in December 2022. Second, in September 2024, for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, pre-diabetes, or type 2 diabetes. Third, in 2025, for the treatment of moderate to severe obstructive sleep apnoea in adults with obesity.

These TGA approvals matter for claims managers because any invoice for Mounjaro in a scheme context must be prescribing within one of these approved indications. Off-label prescribing, for example for general fitness or weight management in someone below the eligibility BMI threshold, has no approved pathway and warrants immediate review.

Why Mounjaro claims are appearing in workers compensation

Obesity and weight gain are recognised secondary complications of workplace injury, particularly musculoskeletal injuries of the back, knees, hips, and shoulders that restrict the injured worker's capacity for physical activity. A worker confined to light duties or no duties for months can experience substantial weight gain as a consequence of reduced mobility, disrupted routine, pain-related inactivity, and the psychological effects of chronic injury. The weight gain workplace injury claim conversation is no longer a fringe one.

That weight gain becomes a clinical complication in its own right. Excess weight places additional mechanical load on injured structures, complicates surgical candidacy for joint replacement or spinal surgery, delays functional recovery, and extends return-to-work timelines. Treating clinicians increasingly frame weight management as a legitimate component of the overall injury treatment plan, and Mounjaro's efficacy profile means it is being prescribed in that context.

Type 2 diabetes is a separate but overlapping pathway. Injured workers with pre-existing or newly diagnosed type 2 diabetes may be prescribed Mounjaro for glycaemic control, and because diabetes is a recognised comorbidity affecting wound healing, cardiovascular risk, and return-to-work capacity, prescriptions in this context may be framed as directly relevant to the claim.

How to assess Mounjaro tirzepatide workers compensation claims

A structured four-part assessment framework provides the most defensible approach.

1. Causal connection

Is the condition being treated with Mounjaro a consequence of the compensable workplace injury? Weight gain caused or materially contributed to by an injury-imposed mobility restriction is a stronger causal argument than pre-existing obesity that predated the injury. Request documentation of the claimant's weight before and after the injury event, and an independent clinical opinion on the causal relationship between the injury, the mobility restriction, and the weight gain.

2. Tirzepatide reasonable and necessary test

The treatment must be clinically appropriate for the claimant's specific condition, consistent with evidence-based guidelines, and proportionate to the injury. Ask the prescribing doctor to document why Mounjaro was selected over conservative management. Has a structured dietary program been implemented under the supervision of a dietitian? Has a supervised exercise or hydrotherapy program been trialled within the limits of the injury? In most cases, conservative management should be genuinely exhausted before a high-cost pharmaceutical intervention is approved.

3. Cost and duration

Mounjaro costs a minimum of $395 per month at the starting dose, rising to approximately $500 per month at the maximum 15 mg dose, with no PBS offset. Critically, Mounjaro is not a short-course treatment. It is a chronic medication intended for ongoing use, and clinical evidence shows that patients who stop the drug regain approximately two-thirds of their lost weight within 12 months. Any approval effectively commits the scheme to an indefinite funding obligation unless a clear and clinically agreed exit plan is documented from the outset.

4. TGA-approved indication

The prescribing doctor must confirm the claimant's BMI meets the eligibility threshold and that the comorbidity criteria are satisfied where BMI is between 27 and 30. A prescription for a claimant who does not meet these eligibility criteria has no valid TGA basis. This is the core of any Mounjaro TGA approved PBS assessment, given that the drug carries no PBS subsidy.

Key clinical risks and the lean mass problem

Understanding the clinical risk profile of Mounjaro matters for claims management for two reasons: it affects the claimant's ongoing treatment complexity, and it can generate new adverse events that interact with the underlying injury claim.

The most common side effects are gastrointestinal. Nausea, vomiting, diarrhoea, and constipation are reported frequently, particularly during the dose escalation phase. These are generally transient but in some claimants are significant enough to require dose adjustment or cessation. More serious risks include acute pancreatitis (approximately 0.2 to 0.4 percent of clinical trial participants), gallbladder disease including gallstones and cholecystitis (approximately 0.6 to 2.5 percent of users), and the potential for acute kidney injury arising from dehydration secondary to gastrointestinal side effects. Rapid weight loss is itself a known risk factor for gallstone formation.

Tirzepatide carries a boxed warning for thyroid C-cell tumours based on dose-dependent findings in animal studies. The relevance to humans is not established, but Mounjaro is contraindicated in any patient with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Claims managers should confirm this contraindication has been screened for before any approval is given. In December 2025, the TGA issued a safety advisory updating contraception guidance for women of reproductive age taking Mounjaro, noting that tirzepatide may reduce the effectiveness of oral contraceptives due to delayed gastric emptying affecting absorption.

The lean mass problem is particularly important in a workers compensation context and is often overlooked in general discussions of GLP-1 obesity workers comp Australia cases. When a person loses weight on tirzepatide, not all of that weight is fat. A body composition substudy within the SURMOUNT-1 trial, using dual-energy X-ray absorptiometry, found that approximately 25 percent of total weight lost was lean mass. For an office worker, this is a secondary concern. For a claimant employed in a manual or physically demanding role who needs to return to heavy work, lean mass loss represents a functional capacity problem. Claims managers approving Mounjaro for physically active occupational groups should require that the treatment plan includes a structured resistance training and protein intake program to mitigate lean mass loss, and should factor functional capacity reassessment into the clinical management schedule.

Compounded tirzepatide: a specific risk to know

From 1 October 2024, the Australian government removed GLP-1 receptor agonist drugs including tirzepatide from the list of substances that can be compounded by Australian pharmacies. Compounded versions of semaglutide and tirzepatide had proliferated through telehealth and online pharmacy channels to meet demand, but they are not subject to TGA quality, safety, or efficacy standards.

Any invoice involving compounded tirzepatide after 1 October 2024 is for a product with no legitimate Australian regulatory pathway. Confirm that any Mounjaro invoice is for the branded, TGA-registered product from Eli Lilly, not a compounded version. The two are distinguishable by product labelling and dispensing pharmacy, and an independent pharmacy review can assist in confirming product legitimacy if there is any doubt.

Key Takeaways

• Mounjaro tirzepatide is TGA-approved for type 2 diabetes, chronic weight management, and obstructive sleep apnoea in adults with obesity, but it is not on the PBS and costs approximately $395 to $500 per month at private prescription rates.
• Mounjaro claims in workers compensation most commonly arise where weight gain is a consequence of injury-imposed mobility restriction, or where the claimant has type 2 diabetes being managed alongside the injury.
• The causal connection assessment is critical: weight gain as a consequence of the compensable injury is a stronger basis for coverage than pre-existing obesity, and independent clinical evidence of the causal relationship is required.
• The reasonable and necessary threshold requires evidence that conservative management including supervised diet and exercise programs has been genuinely trialled first; Mounjaro should not be the first-line intervention.
• Mounjaro is an indefinite, chronic medication and stopping it results in regain of approximately two-thirds of lost weight within 12 months, so any approval must include a documented clinical exit plan and a clear funding boundary for the scheme.
• Approximately 25 percent of weight lost on tirzepatide is lean mass, which requires a resistance training and nutrition program alongside the medication for physically active occupational groups.
• Compounded tirzepatide has been banned from Australian pharmacy compounding since 1 October 2024; only branded Mounjaro from Eli Lilly has a valid regulatory pathway.

Frequently Asked Questions

Primary sources: Therapeutic Goods Administration (TGA) AusPAR for Mounjaro, 20 September 2024; SURMOUNT-1 trial data published in the New England Journal of Medicine, 2022; Eli Lilly Australia PBS rejection statement, April 2026.